The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
ANIP | +60.9% | +244.08% | +28.04% | +1,414% |
S&P | +15.06% | +95.03% | +14.29% | +323% |
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
The company reported positive third-quarter earnings, and the FDA granted approval for Cortrophin Gel.
Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $211.37M | 53.1% |
Gross Profit | $113.48M | 72.9% |
Gross Margin | 53.69% | 6.1% |
Market Cap | $1.41B | 5.8% |
Market Cap / Employee | $1.58M | 0.0% |
Employees | 897 | 39.7% |
Net Income | $7.73M | 438.0% |
EBITDA | $38.45M | 90.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $217.83M | -9.3% |
Accounts Receivable | $225.65M | 35.9% |
Inventory | 138.3 | 10.3% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $633.20M | 104.8% |
Short Term Debt | $13.22M | 1454.8% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | -1.11% | -3.9% |
Return On Invested Capital | -3.92% | -0.7% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | $71.80M | 453.8% |
Operating Free Cash Flow | $75.81M | 335.4% |
Metric | Q4 2023 | Q1 2024 | Q2 2024 | YoY Change | |
---|---|---|---|---|---|
Price to Earnings | 59.49 | 40.92 | 52.07 | - | |
Price to Book | 3.10 | 2.87 | 3.50 | 3.38 | 14.22% |
Price to Sales | 2.08 | 1.75 | 1.99 | 1.77 | -22.34% |
Price to Tangible Book Value | -5.61 | -5.20 | -7.14 | -7.83 | -233.43% |
Price to Free Cash Flow TTM | 15.53 | 23.29 | 20.65 | 10.70 | -14.83% |
Enterprise Value to EBITDA | -419.30 | 66.00 | 49.59 | 45.46 | -28.91% |
Free Cash Flow Yield | 6.4% | 4.3% | 4.8% | 9.3% | 17.41% |
Return on Equity | -2.1% | -4.9% | -5.2% | -2.8% | -149.83% |
Total Debt | $650.21M | $655.53M | $647.67M | $646.41M | 108.46% |
ANIP earnings call for the period ending September 30, 2021.
ANIP earnings call for the period ending June 30, 2021.
ANIP earnings call for the period ending March 31, 2021.
ANIP earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.